Lotus Pharmaceutical announced on the 10th that its consolidated revenue for May reached NT$1.129 billion, marking a 27% decrease compared to the same month last year. However, cumulative consolidated revenue for the first five months of 2024 totaled NT$8.433 billion, representing an 8% year-on-year increase.

The company noted that its Asian operations achieved a 4% revenue growth in May compared to the previous year, primarily driven by continued strong momentum in Southeast Asia, particularly following the successful integration of the Teva Thailand business.

In South Korea, a longer public holiday period in May led to a temporary revenue dip, as some income was recognized earlier in April. Adjusting for these seasonal factors, combined April and May revenue in Korea still showed a 7% year-on-year growth.

In export markets outside Asia, revenue from hematologic cancer drugs declined by 63% year-on-year, due to the seasonal nature of revenue recognition for these products.

Lotus emphasized that during May, the company continued to expand its global strategic partnerships and strengthen its product portfolio. On May 8, Lotus signed an exclusive agreement with Supernus to introduce Qelbree—a novel non-stimulant, extended-release viloxazine formulation for the treatment of attention-deficit/hyperactivity disorder (ADHD)—into key markets across the Asia-Pacific region.

On the same day, Lotus also secured exclusive rights from LENZ Therapeutics for the development, manufacturing, registration, and commercialization of LNZ100 in South Korea and selected Southeast Asian countries. LNZ100 is the first and only aceclidine-based ophthalmic solution designed to improve near vision in patients with presbyopia.

Resource: 美時5月營收11.29億元、年減27% 前五月營收年增8%